key: cord-0804084-46aw91aj
authors: Brown, Sherry-Ann
title: Cardio-oncology and COVID 19: Lessons learned, past reflections and future deliberations
date: 2022-04-27
journal: Am Heart J Plus
DOI: 10.1016/j.ahjo.2022.100137
sha: b25d41f8635a1565d4aa7ce40c5884c766c9fcaf
doc_id: 804084
cord_uid: 46aw91aj

nan

In cardio-oncology, a myriad of cardiovascular toxicities can result from cancer therapies, primarily radiation therapy and pharmacologic cancer therapies (1) (Fig. 1) . The valves, pericardium, myocardium, coronary arteries, and conduction system of the heart can all be affected. The peripheral vasculature can also be affected by systemic hypertension, pulmonary hypertension, vasospasm, thrombosis stenosis, and vasculitis, yielding a breadth of cardiovascular toxicities in cardio-oncology (1) . Interestingly, there is also a range of cardiovascular toxicities in coronavirus disease of 2019 (COVID-19) (2, 3) . Indeed, the etiology of COVID-19 is different from that of cardio-oncology. In COVID-19, the source of cardiovascular toxicity is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In cardio-oncology, the source of cardiovascular toxicity is cancer therapies. Yet the toxicities in cardio-oncology and COVID-19 are similar in terms of thromboembolism, takotsubo, myocarditis, arrhythmia, heart failure, and acute coronary syndrome (2) . Not only are there commonalities in toxicities between COVID-19 and cardio-oncology, but also there are commonalities in pathophysiology in terms of cytokine release, inflammation, hypoxia, and hypercoagulability (2) . Similarly, dexamethasone, tocilizumab, and bemcentinib are drugs that can be used to treat COVID-19, and have also been used in the treatment of cancer in cardio-oncology (2) . Therapeutic anticoagulation has been studied to treat components of COVID-19 and is also used in cardio-oncology (2) .

As we move forward in studying, understanding, caring for patients, and educating others and each other regarding cardio-oncology and COVID-19, the continued assessment of underlying factors and solutions to address health disparities in cardiovascular toxicities observed in cardio-oncology, and COVID-19 is necessary (2) ( Table 1) . Additionally, more precise risk prediction in cardio-oncology and COVID-19 patients belonging to communities and populations that experience health disparities, as well as in the general population, needs to take place (2) . We must consider how to predict who is most at risk for developing cardiovascular toxicity from cancer therapies as well as who is most at risk for severe illness or death from COVID-19. Other important points to consider in both cardio-oncology and COVID-19 are the short-term and long-term sequelae of inflammation, endothelial dysfunction, macrovascular and microvascular dysfunction, among others, that exist (2).

Along the path of survivorship and understanding survivorship, we are much further along in cardio-oncology than we are in COVID-19, yet there is much further for us to advance. As we learn more about how to screen, approach surveillance, and manage longterm survivorship in cardio-oncology, we must do the same in COVID-19, as we learn more about both conditions, moving forward, together. We must therefore consider the need to build more clinics across our practices for cardio-oncology, that are also cognizant of the effects of COVID-19 (4). To accomplish this, a three-pronged virtual hybrid approach can be used (4) . This virtual hybrid approach includes information seeking, information gathering, and information sharing. Information seeking focuses on where there are clinics already in place. Focus should be placed on literature reviews on how others have built their cardiooncology clinics, as well as networking and attending regional and national meetings. Information gathering addresses where the clinic will be built, learning about existing resources and the needs and patients in the partnering cancer center, and networking with stakeholders. Once the clinic has been built, information sharing is key. Share qualitative data and quantitative data about how you have been able to build and incorporate virtual health into your hybrid cardio-oncology practice, recognizing that some of your patients will also be coming in who currently, previously, or in the future would have COVID-19 (4). To J o u r n a l P r e -p r o o f protect our patients, we must minimize in-person visits, making most visits virtual and safe, to protect the patient from COVID-19, and to protect each other, as well as our trainees (5) . Thus, as trainees learn, they are learning in virtual didactics and conferences, from social media "Tweetorials", learning by experiencing telemedicine and remote monitoring, and by individualizing cardiotoxicity surveillance, whether in the inpatient or outpatient setting (5)(Brown et al, Heart Failure Clinics, Invited, In Press). Therefore, virtual care for our patients, telemedicine and remote monitoring, partnering with virtual communication, can expand the capacity of each other and our trainees to collaborate across each institution, across institutions, and across the world (4). Truly, we are all in this inevitable dance between cardio-oncology and COVID-19, and between cardio-oncology and oncology (6), together. We must work together in research and innovation, education, awareness, support, collaboration, and community, to improve the health, healing, and well-being of all of our patients in cardio-oncology or COVID-19, or both.

SAB: Study design, data analysis, result interpretation, manuscript preparation and paper revisions; approved the completed version.

Used with permission (2).

Mechanisms of left ventricular cardiomyopathy Elucidate mechanisms and optimal management of left ventricular systolic dysfunction in Cardio-Oncology Elucidate mechanisms and optimal management of left ventricular systolic dysfunction in COVID-19

Immune system activation Analyze pathophysiology and optimal management of immune response, cytokine release syndrome, and autoimmune adverse effects from ICIs or CAR-T cell therapy

Analyze pathophysiology and optimal management of immune response, cytokine release syndrome, and related adverse effects in COVID-19

Long-term sequelae of inflammation 

Preventive Cardio-Oncology: The Time Has Come

Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology

ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO)

A virtual-hybrid approach to launching a cardio-oncology clinic during a pandemic

Cardio-oncology Training in the COVID-19

Cancer And The Heart: The Inevitable Dance. Your Heart And Cancer